Cox TM - Search Results

1

Innovative treatments for lysosomal diseases.

Cox TM. Cox TM. Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):275-311. doi: 10.1016/j.beem.2015.01.001. Epub 2015 Jan 24. Best Pract Res Clin Endocrinol Metab. 2015. PMID: 25987179 Review.

2

The cellular pathology of lysosomal diseases.

Cox TM, Cachón-González MB. Cox TM, et al. J Pathol. 2012 Jan;226(2):241-54. doi: 10.1002/path.3021. J Pathol. 2012. PMID: 21990005 Review.

3

Damage at the cellular and organ levels in LSDs: possibility for prevention/reversibility with ERT.

Cox TM, Beck M. Cox TM, et al. Acta Paediatr Suppl. 2006 Apr;95(451):75-6. doi: 10.1111/j.1651-2227.2006.tb02394.x. Acta Paediatr Suppl. 2006. PMID: 16720470 No abstract available.

4

Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.

Cox TM. Cox TM. Curr Opin Investig Drugs. 2010 Oct;11(10):1169-81. Curr Opin Investig Drugs. 2010. PMID: 20872320 Review.

5

Reversibility of neuropathology in Tay-Sachs-related diseases.

Cachón-González MB, Wang SZ, Ziegler R, Cheng SH, Cox TM. Cachón-González MB, et al. Among authors: cox tm. Hum Mol Genet. 2014 Feb 1;23(3):730-48. doi: 10.1093/hmg/ddt459. Epub 2013 Sep 20. Hum Mol Genet. 2014. PMID: 24057669 Free PMC article.

6

Roscoe O. Brady: Physician whose pioneering discoveries in lipid biochemistry revolutionized treatment and understanding of lysosomal diseases.

Aerts JM, Cox TM. Aerts JM, et al. Among authors: cox tm. Blood Cells Mol Dis. 2018 Feb;68:4-8. doi: 10.1016/j.bcmd.2016.10.030. Epub 2017 Jan 12. Blood Cells Mol Dis. 2018. PMID: 28118958 No abstract available.

7

Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.

Roos JCP, Daniels MJ, Morris E, Hyry HI, Cox TM. Roos JCP, et al. Among authors: cox tm. Mol Genet Metab. 2018 Feb;123(2):177-183. doi: 10.1016/j.ymgme.2017.06.008. Epub 2017 Jun 21. Mol Genet Metab. 2018. PMID: 28822614 Free PMC article.

8

Rare diseases and effective treatments: are we delivering?

Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G. Luzzatto L, et al. Among authors: cox tm. Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5. Lancet. 2015. PMID: 25752159 No abstract available.

9

Brexit and rare diseases: big risk, bigger opportunity?

Hyry HI, Cox TM, Roos JC. Hyry HI, et al. Among authors: cox tm. Curr Med Res Opin. 2017 Apr;33(4):783-784. doi: 10.1080/03007995.2017.1284053. Epub 2017 Mar 9. Curr Med Res Opin. 2017. PMID: 28100081

10

Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Lecommandeur E, Baker D, Cox TM, Nicholls AW, Griffin JL. Lecommandeur E, et al. Among authors: cox tm. J Lipid Res. 2017 Jul;58(7):1306-1314. doi: 10.1194/jlr.M073395. Epub 2017 Apr 4. J Lipid Res. 2017. PMID: 28377426 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters